and was conducted according to the Declaration of Helsinki. Written consent was obtained from all participating family members, and only subjects older than 18 years were included. Archival, paraffin-embedded tissue from both families, sporadic cutaneous and uveal melanomas, sporadic common melanocytic nevi, Spitz nevi and atypical Spitz tumors were retrieved from the
l e t t e r s Common acquired melanocytic nevi are benign neoplasms that are composed of small, uniform melanocytes and are typically present as flat or slightly elevated pigmented lesions on the skin. We describe two families with a new autosomal dominant syndrome characterized by multiple, skin-colored, elevated melanocytic tumors. In contrast to common acquired nevi, the melanocytic neoplasms in affected family members ranged histopathologically from epithelioid nevi to atypical melanocytic proliferations that showed overlapping features with melanoma. Some affected individuals developed uveal or cutaneous melanomas. Segregating with this phenotype, we found inactivating germline mutations of BAP1, which encodes a ubiquitin carboxy-terminal hydrolase. The majority of melanocytic neoplasms lost the remaining wild-type allele of BAP1 by various somatic alterations. In addition, we found BAP1 mutations in a subset of sporadic melanocytic neoplasms showing histological similarities to the familial tumors. These findings suggest that loss of BAP1 is associated with a clinically and morphologically distinct type of melanocytic neoplasm.
We report a type of melanocytic neoplasm that was inherited in an autosomal dominant pattern in two unrelated families and that was clinically, histopathologically and genetically distinct from common acquired nevi (Fig. 1a) . Beginning in the second decade of life, affected family members progressively developed skin-colored to reddish-brown, dome-shaped to pedunculated, well-circumscribed papules with an average size of 5 mm ( Fig. 1b and Supplementary  Figs. 1-4) . The number of tumors per individual varied markedly, ranging from 5 to over 50. No intellectual disabilities or dysmorphic features were identified in affected individuals.
Histopathological examination identified primarily dermal tumors composed entirely or predominantly of epithelioid melanocytes with abundant amphophilic cytoplasm and prominent nucleoli. The melanocytes often contained large, vesicular nuclei that varied substantially in size and shape ( Fig. 1c and Supplementary Figs. 5-7) . The cytological features of some of the cells were reminiscent of Spitz nevi; however, characteristic features (such as epidermal hyperplasia, hypergranulosis, Kamino bodies, clefting around junctional melanocytic nests and spindle-shaped melanocytes) frequently seen in Spitz nevi were consistently absent. In addition, 37 of 42 (88%) tumors in the families showed mutations in the BRAF proto-oncogene, which are typically absent in Spitz nevi 1 .
Some of the neoplasms showed one or more atypical features such as high cellularity, considerable nuclear pleomorphism and several chromosomal aberrations. These tumors were classified as 'neoplasms of uncertain malignant potential' , and the affected individuals were managed as if they had melanoma ( Supplementary Fig. 8 ). Both families were identified because of the occurrence of multiple epithelioid melanocytic tumors, but, in each family, one affected individual had uveal melanoma, and three members of family 2 had been diagnosed with cutaneous melanoma ( Fig. 1a and Supplementary Table 1 ).
We analyzed 22 melanocytic neoplasms from three affected individuals (II-1, II-4 and II-7) in family 1 by array-based comparative genomic hybridization (aCGH). We found losses affecting the entire chromosome 3 or portions of the short arm of chromosome 3 in 50% of tumors. The smallest overlap of the deleted regions encompassed 5.8 Mb, extending from position 47,976,758 to 53,848,761 (hg 18 assembly) and encoded at least 150 known genes ( Fig. 2a) .
The frequent loss of the 3p21 region suggested a second hit 2 resulting in the elimination of the remaining wild-type allele of a mutated tumor suppressor gene in this region. To support this hypothesis, Germline mutations in BAP1 predispose to melanocytic tumors l e t t e r s we reconstructed the haplotypes of six members of family 1 with SNP arrays. Affected siblings in the second generation (II-1, II-4 and II-7) inherited the same maternal copy of the 3p21 region, whereas the unaffected brother (II-5) received the other maternal 3p21 copy ( Supplementary Fig. 9a ). SNP arrays showed that, in all tumors with chromosome 3 loss, the paternal copy of chromosome 3 was lost, whereas the maternal copy was retained ( Supplementary Fig. 9b ).
In conclusion, these data suggested that a mutated gene in the 3p21 region was inherited from the maternal side of the family.
To identify the mutated gene, we sequenced the minimally deleted region of chromosome 3 in two affected (I-2 and II-4) and two unaffected (I-1 and II-5) subjects from family 1 using an in-solution hybrid capture technique followed by massively parallel sequencing 3 . This analysis identified a frameshift mutation in BAP1 (c.1305delG, p.Gln436Asnfs*135) that was subsequently found to segregate with the phenotype (Fig. 2b and Supplementary  Fig. 10 ). To rule out BAP1 germline mutations in the general population, we reviewed sequence data from 629 individuals in the 1000 Genomes Project database (see URLs). No truncating mutations were found, indicating that BAP1 germline mutations are infrequent in the general population.
We assessed the status of the second BAP1 allele in 29 skin tumors and in the uveal melanoma (I-2) from family 1 (Supplementary Table 2 ). All tumors in which loss of 3p21 was detected previously by aCGH also showed loss of the wild-type BAP1 allele in the sequencing electropherogram ( Supplementary Fig. 11a ). In five additional cases without loss of the 3p21 region, the electropherogram showed markedly suppressed residual wild-type sequences, indicating that the neoplastic cells had lost the wild-type BAP1 allele through copy-number-neutral mechanisms, resulting in maternal uniparental disomy (Supplementary Fig. 11b ). In four other neoplasms without 3p21 deletions, we found additional acquired somatic nonsense (two cases), frameshift (one case) and missense (one case) mutations in BAP1 (Supplementary Fig. 11c ). Immunohistochemistry for BAP1 showed loss of nuclear expression in all melanocytic neoplasms, including the tumors without detectable alteration of the wild-type BAP1 allele. In summary, these data suggest that the remaining wild-type allele of BAP1 is lost by various somatic alterations in the melanocytic tumors.
In family 2, we found a different germline mutation in BAP1 that segregated with the phenotype and removed the acceptor splice site at the last exon (c.2057-2A>G, p.Met687Glufs*28; Fig. 2b ). Analysis of cDNA from two affected family members confirmed that the last intron was not removed by splicing ( Supplementary Fig. 12 ). In family 2, inactivation of the remaining wild-type BAP1 allele was found in 9 of 13 skin tumors, in the uveal melanoma (II-1) and in the cutaneous melanoma from individual II-3 ( Fig. 3a-d and Supplementary Table 3 ). The metastatic melanoma of individual II-6 did not show loss of I   1   II   2   1  2  3  4  5  6   1  2  3  4  5  6  7   III   1  2  3  4  5   1  2  3  4  6 1 0 2 0 VOLUME 43 | NUMBER 10 | OCTOBER 2011 Nature GeNetics l e t t e r s heterozygosity of BAP1, but no additional tissue was available to investigate alternative mechanisms of BAP1 inactivation. Aside from the elevated, skin-colored melanocytic neoplasms, common acquired nevi (flat, brown maculae) were also excised from four subjects (II-3, III-3, III-4, III-5). Histopathologically, these nevi were composed of small uniform melanocytes and showed strong nuclear expression of BAP1 by immunohistochemistry (Supplementary Fig. 13) .
To address the role of BAP1 mutations in sporadic melanocytic neoplasms, we sequenced BAP1 in 156 randomly selected tumors from patients without family history of melanocytic neoplasms: common nevi with uniform small melanocytes (n = 28); Spitz nevi (n = 17); neoplasms with overlapping features between Spitz nevus and melanoma (so-called 'atypical Spitz tumors' , n = 18); primary melanomas originating from acral skin (n = 15), mucosa (n = 15) or skin with (n = 15) or without (n = 15) chronic sun-induced damage and uvea (n = 33). Thirteen (40%) uveal melanomas, two (11%) atypical Spitz tumors and three (5%) of the melanomas (two melanoma on skin without chronic sun-induced damage and one acral melanoma) had somatic BAP1 mutations. No mutations were found in the other categories ( Supplementary Tables 4-8) . The mutation frequency seen in uveal melanoma is similar to that found in a recent report 4 . Two of five sporadic cutaneous melanomas that arose in nevi harbored BAP1 mutations. In both cases, the BAP1 mutations were absent in the nevus portion, suggesting that loss of function of BAP1 may have a role in progression from nevus to melanoma in some cases ( Fig. 4a-g) .
The two atypical Spitz tumors with somatic BAP1 mutations had similar morphologic features to the melanocytic neoplasms seen in both families, lacked immunohistochemical expression of BAP1 and harbored BRAF mutations (Supplementary Fig. 14) . This finding suggests that biallelic inactivation of BAP1 is associated with a clinically and morphologically distinct type of melanocytic neoplasm. Histopathologically, the tumors ranged from intradermal nevi composed of bland epithelioid melanocytes to atypical proliferations of epithelioid melanocytes with morphological and cytogenetic features overlapping with melanoma. Such tumors have been previously subsumed under the category of 'spitzoid' melanocytic neoplasms because they share cytological features with Spitz nevi.
As illustrated by these families, inheriting one mutant copy of BAP1 results in a large number of these neoplasms. In aggregate, several hundred papular melanocytic tumors were present in affected family members, whereas the number of melanomas was substantially lower. This indicates that the risk of malignant progression in individual Figure 3 Biallelic BAP1 loss is associated with characteristic histological features in familial melanocytic neoplasms. (a-c) A melanocytic neoplasm from individual III-3, family 2 (a), presents as a combined lesion with an area of small cells (common acquired nevus) on the left (b) and an area of large epithelioid cells on the right (c). Scale bars in b,c, 50 µm. Fluorescence in situ hybridization (red signal: 3p21 (BAP1); orange: 3p25 (control); green: 4p12 (control)) shows loss of BAP1 in the area with large epithelioid melanocytes (inset in c: one red BAP1 signal but two orange and green control signals per nucleus; scale bar, 10 µm) but no loss in the region of the common nevus (inset in b: two signals of each probe; scale bar, 10 µm). tumors is low and that biallelic loss of BAP1 in conjunction with mutations in BRAF is not sufficient for melanoma formation in the skin. A recent report 4 proposed that biallelic loss of BAP1 in uveal melanoma, which carry mutations in GNAQ 5 or GNA11 (ref. 6) but not in BRAF, marks the transition to metastatic disease. Our findings may indicate that the role of BAP1 in melanocytic neoplasia depends on the associated oncogene, the cell of origin or both. BAP1 was originally discovered as a binding partner of BRCA1 and has been functionally implicated in DNA damage response 7, 8 , as well as in regulation of apoptosis, senescence and the cell cycle 9 . Its Drosophila counterpart Calypso is involved in chromatin remodeling, which was shown to oppose the monoubiquitination activity of polycomb repressive complex 1, a critical component of transcriptional silencing 10 . Mutations and deletions in BAP1 have been reported in breast and lung cancers [11] [12] [13] , but none of the individuals in our study developed breast or lung cancers.
In summary, we describe a new autosomal dominant syndrome that is caused by germline mutations of BAP1, characterized by a high penetrance of melanocytic neoplasms with distinctive clinical and histopathological features and possibly associated with an increased risk for uveal and cutaneous melanoma.
URLs. 1000 Genomes Project Database, http://www.1000genomes. org/; DNA-Chip Analyzer, http://biosun1.harvard.edu/complab/ dchip/; Agilent's eArray, https://earray.chem.agilent.com/erray/; Genome Analysis Toolkit, http://www.broadinstitute.org/gsa/wiki/ index.php/Local_realignment_around_indels; VarScan (v2.2), http:// varscan.sourceforge.net/.
MeThodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession numbers. The mutation nomenclature is based on the following National Center for Biotechnology Information (NCBI) reference sequences: BAP1 cDNA, NM_004656.2; BAP1 protein, NP_ 004647.1; BRAF cDNA, NM_004333.4; BRAF protein, NP_004324.2; GNAQ cDNA, NM_002072.3; GNAQ protein, NP_002063.2; GNA11 cDNA NM_002067.2; GNA11 protein, NP_002058.2.
